These mutations arise under the selective pressure of AI therapy, are detectable in circulating tumor cells and metastases, confer ligand-independent ER transcriptional activity, and permit cell survival and proliferation under long-term estrogen deprivation (LTED) engendered by AI therapy (12, 13). The gene discussed is ESR1; the disease is neoplasm.